View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 15, 2020

Russia grants approval to second vaccine for Covid-19

Russian health authorities have granted approval to a second Covid-19 vaccine developed by the Vector State Virology and Biotechnology Center in Siberia.

Health authorities in Russia have granted approval to a second Covid-19 vaccine developed by the Vector State Virology and Biotechnology Center in Siberia.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Researchers tested the vaccine, EpiVacCorona, in 100 participants in Phase I and II trials prior to receiving provisional registration.

Trial results remain unpublished and the Phase III trial on approximately 30,000 participants should begin in the next couple of months.

This is the second Covid-19 vaccine to receive approval and bypass accepted scientific protocol in a bid to fight against the virus.

Bloomberg quoted Russian President Vladimir Putin as saying: “We need to increase production of our first and now our second vaccine. First of all, we should supply the domestic market.

“Russia also plans to work with foreign partners to boost output.”

In August, Russia awarded regulatory approval to Sputnik V and became the world’s first country to register a Covid-19 vaccine for use.

Developed by the Gamaleya National Research Institute of Epidemiology and Microbiology in Russia, Sputnik V derives from human adenoviral vector platform. The vaccine is currently in Phase III trials on 40,000 participants.

Preliminary results will be available next month, with full data anticipated for next year.

Over 50 countries expressed interest in procuring the vaccine, with the developers receiving orders for 1.2 billion doses since its registration.

Last month, India-based pharma company Dr Reddy’s Laboratories partnered with the Russian Direct Investment Fund (RDIF) for trials and supply of Sputnik V vaccine.

Moscow’s Chumakov Federal Scientific Center also developed a third vaccine, which should be registered by December. Phase II trials will begin on 19 October.

Meanwhile, Turkey is ready to start the human trials for two potential vaccines for Covid-19.

Erciyes University and Ankara University are developing the vaccines.

Turkey Health Minister Fahrettin Koca said that tests concluded for five potential vaccines on animals.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology